- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01705015
Organ Transplantation Rehabilitation: Effect of Bedside Exercise Device and Activity Reinforcement
October 15, 2012 updated by: National Taiwan University Hospital
Organ Transplantation Rehabilitation: Effect of Bedside Exercise Device and Activity Reinforcement for Heart or Liver Transplantation Recipients in Early Postoperative Period
The aims of this 3-year randomized, single-blinded clinical trial are to compare the effect of high and low feedback about performance on the bedside exercise device in heart or liver transplantation recipients during the hospitalization immediately after transplantation.
The hypotheses of the study are heart/liver transplantation recipients who have high feedback about performance on the bedside exercise device will progressively increase their level of exercise over the course of their hospitalization, more independent in ambulation level, better walking speed and 6-minute walk test at discharge, and better cardiorespiratory fitness at 4-8 weeks after transplantation than those who receive low feedback.
The adult patients who newly receive heart or liver transplantation at National Taiwan University Hospital will be evaluated for eligibility of the study in the acute postoperative period.
The study will be conducted in both the intensive care unit and ward environments.
The study subjects will be randomized to either high or low feedback about performance on the bedside exercise device which uses hand/foot pedals that record exerted forces against adjustable resistances, measure repetitions of upper and lower extremity cycling movements, and give feedback about performance via a wireless internet connection.
The study will also monitor the amount of daily movement activity of all subjects in this trial by using triaxial accelerometers, and the activity recognition algorithms developed by engineers and computer scientists at University of California Los Angeles.
The outcome measures include level of independence for walking, walking speed, 6-minute walk test, and cardiopulmonary exercise testing by the blinded observers.
The study expects to enroll at least 50 heart transplantation recipients and 60 liver transplantation recipients in 3 years.
The results of this study will offer much insight into activity levels of heart or liver transplantation recipients during early postoperative period.
Besides, heart transplantation recipients will receive routine phase I cardiac rehabilitation program by the physical therapists during the study but not liver transplantation recipients.
We might be able to evaluate the interaction effects of routine physical therapy and UCFit exercise among our study subjects.
Our data will also provide insight into just how active or inactive transplantation recipients may be and help generate ideas of organ transplantation rehabilitation program to increase their fitness-related activity prior to discharge.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
110
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: SSU-YUAN CHEN, MD, PhD
- Phone Number: 67753 +886-2-23123456
- Email: ssuyuan@ntu.edu.tw
Study Locations
-
-
-
Taipei, Taiwan, 10002
- Recruiting
- National Taiwan University Hospital
-
Principal Investigator:
- SSU-YUAN CHEN, MD, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- just received heart or liver transplantation at National Taiwan University Hospital during admission
- over age 18 years old
- living and walking independently, based on the Functional Independence Measure of activities of daily living, within 6 weeks prior to admission
- no major contraindication to participating in light-to-moderate exertion and Per their primary physician in the hospital
- be able to follow and retain 3 minutes later verbal directions to carry out a simple upper and a lower extremity repetitive exercise, such as leg lifts.
Exclusion Criteria:
- unlikely to survive for 3 months
- body mass index >30
- progressive decline in medical status by symptoms or laboratory data (e.g., new onset renal failure or transplant rejection) at the time of entry that is likely to interfere with exercise capacity (subjects may participate once stable);
- skin breakdown that will interfere with positioning for exercise
- inability to lift each leg so that the heel is 6 inches above the bed
- cardiopulmonary contraindication to modest exercise per the care team, such as angina, deep vein thrombosis or hypoxia
- fractures or contractures that prevent use of an extremity for pedaling
- A hemiparesis that is mild enough to permit voluntary placement of the hand and foot onto the apparatus will not be an exclusion, but lesser motor control will.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: UCFit plus direct feedback about exercise
Subjects assigned to higher feedback will be encouraged to look at the summary of daily data about pedaling and will be encouraged to progress activity - more repetitions per minute (RPM range from 10-60), more frequent sessions (up to 3 times daily), longer sessions (from 5-20 minutes), and exertion against larger forces (no resistance, mild, moderate) for the legs.
These subjects will also be encouraged to carry out pedaling with the upper extremities once a day, if the arms are free of lines that could be damaged.
Progression of leg exercises would be within the capability and motivation of each subject, but would not exceed increments of 10% from one day to the next in any one of these parameters.
Graphical displays that can be used for feedback will be available at the patient's bedside.
The staff, patient and family will be able to view these bar graphs.
|
|
Placebo Comparator: UCFit plus encouraged exercise
These subjects will receive a graph of the total number of minutes cycled each day and the average RPMs.
The coordinator will only encourage these subjects to try to increase their total cycling time.
These bar graphs will not be posted, but will be left by the bedside.
|
UCFit plus encouraged exercise
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
A.Level of independence for walking 150 feet and the ratio of subjects who achieve independence in walking 150 feet. B. Walking speed for 50 feet. C. 6-minute walk test. D. Findings of cardiopulmonary exercise testing
Time Frame: At discharge of hospital stay, an expected average of 5 weeks, up to 8 weeks after transplantation
|
A.* Level of independence for walking 150 feet (or only for 50 feet if that is feasible) and the ratio of subjects who achieve independence in walking 150 feet in each group based on the criteria of the 7-level scale; B.* Walking speed for 50 feet (or for a subject's lesser feasible distance);C.*
6-minute walk test (including the walking distance in 3 and 6 minutes); D.* Peak oxygen uptake of cardiopulmonary exercise testing (if the exercise testing is not feasible at discharge, findings within 8 weeks after transplantation will be acceptable)
|
At discharge of hospital stay, an expected average of 5 weeks, up to 8 weeks after transplantation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
A.Total amount of exercise. B.Short Form-36. C. Length of stay in the intensive care unit and hospital. D.Rate of rehospitalization. E.Adverse responses and complications related to exercise.
Time Frame: At discharge of hospital stay, an expected average of 5 weeks, up to 8 weeks after transplantation, and 30 days after discharge
|
A.* Total number of daily sessions and total minutes of exercise during the hospital stay; B.* Health-related quality of life by Short Form-36 questionnaire; C.* Length of stay in the intensive care unit and hospital post transplantation; D.* Rate of rehospitalization within 30 days of discharge; E.* Adverse responses and complications related to exercise.
|
At discharge of hospital stay, an expected average of 5 weeks, up to 8 weeks after transplantation, and 30 days after discharge
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: SSU-YUAN CHEN, MD PhD, National Taiwan University Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2012
Primary Completion (Anticipated)
August 1, 2015
Study Registration Dates
First Submitted
September 11, 2012
First Submitted That Met QC Criteria
October 10, 2012
First Posted (Estimate)
October 12, 2012
Study Record Updates
Last Update Posted (Estimate)
October 16, 2012
Last Update Submitted That Met QC Criteria
October 15, 2012
Last Verified
September 1, 2012
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- NSC101-2314-B-002-006-MY3
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Transplantation
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCzechia, France, Italy, Poland, United Kingdom
-
The Hospital for Sick ChildrenCompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCanada
-
Astellas Pharma Europe Ltd.TerminatedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationSpain, Australia, France, Germany, Canada, Italy, United Kingdom, Belgium, South Africa, Switzerland, Sweden, United States, Austria, Brazil, Czechia, Denmark, Finland, Hungary, Ireland, Mexico, Netherlands, New Zealand, Poland
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Astellas Pharma Europe Ltd.Active, not recruitingLiver Transplantation | Kidney Transplantation | Heart Transplantation | Lung Transplantation | Intestine TransplantationBelgium, Czechia, France, Germany, Italy, Poland, United Kingdom
-
NovartisCompletedLiver Transplantation | Kidney TransplantationSwitzerland
-
University of Wisconsin, MadisonTerminatedLiver Transplantation | Kidney TransplantationUnited States
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingLiver Transplantation | Kidney TransplantationFrance
-
Astellas Pharma China, Inc.CompletedLiver Transplantation | Kidney TransplantationChina
Clinical Trials on direct feedback about exercise
-
Kai Lutz, PhDUniversity of ZurichCompletedMotor Learning | Motor PerformanceSwitzerland
-
University Medical Center GroningenRecruiting
-
University of ValenciaUnknown
-
The University of Hong KongTung Wah Group of HospitalsCompleted
-
Cleveland State UniversityCompleted
-
Tel-Aviv Sourasky Medical CenterKU Leuven; Michael J. Fox Foundation for Parkinson's ResearchCompletedParkinson DiseaseIsrael, Belgium
-
University of OsloUllevaal University Hospital; University of Chicago; Norwegian Air Ambulance... and other collaboratorsCompletedCardiac ArrestNorway, Sweden, United Kingdom
-
Dana-Farber Cancer InstituteHarvard Medical School (HMS and HSDM); Brigham and Women's Hospital; University... and other collaboratorsCompleted
-
Indiana UniversityNational Institute of Neurological Disorders and Stroke (NINDS)Recruiting
-
US Department of Veterans AffairsCompletedPulmonary Disease, Chronic ObstructiveUnited States